To this end, a CRISPR/dCasRx strategy was employed to induce TIMP1 exon 4–5 exclusion in vitro and in vivo, showing promising therapeutic value of targeting TIMP1 alternative splicing in CRC. Here, TIMP1 is linked to colorectal carcinoma.